Tradegate
30.09.26 | 17:59
9,650 Euro
+1,58 % +0,150
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,400 | 9,500 | 02.10. | |
| 9,300 | 9,650 | 02.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Silence Therapeutics auf der Cantor-Gesundheitskonferenz: Fortschritte bei Divesiran | 5 | Investing.com Deutsch | ||
| 02.09. | Silence Therapeutics plc: Silence Therapeutics to Participate in Three September Investor Conferences | 619 | Business Wire | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in... ► Artikel lesen | |
| 14.08. | Silence Therapeutics schließt Kapitalerhöhung über 201,3 Mio. Dollar erfolgreich ab | 9 | Investing.com Deutsch | ||
| 14.08. | Silence Therapeutics closes $201.3M public offering | 1 | Investing.com | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.08. | Silence Therapeutics plc: Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs | 690 | Business Wire | Silence Therapeutics plc, (Nasdaq: SLN), ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced the... ► Artikel lesen | |
| 12.08. | Silence Therapeutics prices upsized $175M ADS offering at $13.50 each | 5 | Seeking Alpha | ||
| 12.08. | Silence Therapeutics prices $175M public offering at $13.50 per ADS | 3 | Investing.com | ||
| 12.08. | Silence Therapeutics plc: Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering | 1.160 | Business Wire | Silence Therapeutics plc ("Silence" or the "Company"), a global clinical-stage biotechnology company developing novel short interfering RNA ("siRNA") therapies, today announced that it has priced... ► Artikel lesen | |
| 11.08. | Morgan Stanley maintains Overweight rating on Silence Therapeutics | 14 | Seeking Alpha | ||
| 10.08. | Silence Therapeutics startet öffentliches Angebot über 150 Millionen US-Dollar | 18 | Investing.com Deutsch | ||
| 10.08. | Silence Therapeutics launches $150M ADS offering | 2 | Seeking Alpha | ||
| 10.08. | Silence Therapeutics stock surges as divesiran trial results fuel optimism | 1 | Seeking Alpha | ||
| 10.08. | Silence Therapeutics reports positive phase 2 trial results | 9 | Investing.com | ||
| 10.08. | Silence Therapeutics: Divesiran erreicht primären Endpunkt in Phase-2-Studie | 11 | Investing.com Deutsch | ||
| 10.08. | Silence Therapeutics plc: Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile | 598 | Business Wire | Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate 69% Both divesiran... ► Artikel lesen | |
| 10.08. | Silence Therapeutics plc - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 10.08. | Silence Therapeutics GAAP EPS of -$0.09 beats by $0.08 | 2 | Seeking Alpha | ||
| 10.08. | Silence Therapeutics plc - 8-K, Current Report | 10 | SEC Filings | ||
| 10.08. | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results | 2.585 | Business Wire | Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial and business results for the second... ► Artikel lesen | |
| 10.08. | Silence Therapeutics: Aktie schießt vor wichtigen Studiendaten in die Höhe | 13 | Investing.com Deutsch |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| GILEAD SCIENCES | 128,68 | +0,09 % | Assembly Biosciences: Herpes-Countdown mit Gilead | ||
| ELI LILLY | 1.019,20 | +0,33 % | Eli Lilly's Jaypirca gains additional indication for untreated leukemia, lymphoma | ||
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| INNOCAN PHARMA | 1,265 | -0,78 % | Innocan Pharma Corporation: VALITIC Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA | HERZLIYA, Israel and CALGARY, Alberta, Sept. 29, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (OTCQB: INNPF) ("Innocan" or the "Company"), through B.I. Sky Global Ltd., its consumer... ► Artikel lesen | |
| VIATRIS | 15,400 | -1,52 % | Dividendenbekanntmachungen (21.08.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,0642 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,29 USD 0,2483 EUR AMGEN... ► Artikel lesen | |
| SYNBIOTIC | 0,834 | -1,88 % | Original-Research: SYNBIOTIC SE (von NuWays AG): Under review | Original-Research: SYNBIOTIC SE - from NuWays AG
24.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 0,837 | -1,06 % | ORGANIGRAM GLOBAL INC. - 6-K, Report of foreign issuer | ||
| IONIS PHARMACEUTICALS | 38,360 | -0,85 % | Genentech, Ionis Reveal Positive Interim Data From Phase III Sefaxersen Study In IgA Nephropathy | SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), and partner Ionis Pharmaceuticals, Inc. (IONS) announced Wednesday positive... ► Artikel lesen | |
| SNDL | 1,112 | +0,54 % | Immortal Dragons: Sundial Initiative Advisor Boyang Wang Sponsors Nakauchi Lab's Work on "Bodyoids" | SINGAPORE, SG / ACCESS Newswire / July 30, 2026 / Boyang Wang, advisor to the Sundial Initiative and founder and CEO of the longevity fund Immortal Dragons, has sponsored the Nakauchi Lab, led by stem... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 19,700 | -1,50 % | Assembly Biosciences: Jetzt startet der Herpes-Countdown | ||
| QUANTUM BIOPHARMA | 2,922 | -3,18 % | Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 0,900 | 0,00 % | Happy Belly Food Group Inc.: Happy Belly Food Group Announces Grand Opening of First U.S. Heal Wellness Location in Lubbock, Texas | Toronto, Ontario--(Newsfile Corp. - September 29, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| PENTIXAPHARM | 1,825 | -1,35 % | EQS-Adhoc: Pentixapharm Holding AG: Bafin schließt Bilanzkontrolle des Konzernabschlusses 2024 mit Fehlerfeststellung ab | EQS-Ad-hoc: Pentixapharm Holding AG / Schlagwort(e): Sonstiges
Pentixapharm Holding AG: Bafin schließt Bilanzkontrolle des Konzernabschlusses 2024 mit Fehlerfeststellung ab
02.10.2026... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 196,00 | +0,36 % | Cantor Fitzgerald reiterates Neutral rating on Alnylam stock |
Das Unternehmen SILENCE THERAPEUTICS PLC ADR kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,58 % bei einem Aktienkurs von 9,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.